BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
(Adnkronos) – NEW YORK, Oct. 31, 2023 /PRNewswire/ — M.S.Q. Ventures (“MSQ”) is pleased to announce that its client, BioLineRx Ltd. (“BioLineRx”) (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences
